Loading…
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combinatio...
Saved in:
| Published in: | Future oncology (London, England) England), 2021-02, Vol.17 (5), p.491-501 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c437t-da4ccc9be4d856443e3905ec47f95d1563496f9d088588af5c1762c5e5effa1b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c437t-da4ccc9be4d856443e3905ec47f95d1563496f9d088588af5c1762c5e5effa1b3 |
| container_end_page | 501 |
| container_issue | 5 |
| container_start_page | 491 |
| container_title | Future oncology (London, England) |
| container_volume | 17 |
| creator | Chung, Hyun Cheol Bang, Yung-Jue S Fuchs, Charles Qin, Shu-Kui Satoh, Taroh Shitara, Kohei Tabernero, Josep Van Cutsem, Eric Alsina, Maria Cao, Zhu Alexander Lu, Jia Bhagia, Pooja Shih, Chie-Schin Janjigian, Yelena Y |
| description | Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Clinical trial registration: NCT03615326 (
) |
| doi_str_mv | 10.2217/fon-2020-0737 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8411394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2459346871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-da4ccc9be4d856443e3905ec47f95d1563496f9d088588af5c1762c5e5effa1b3</originalsourceid><addsrcrecordid>eNp1kU1vFSEUhonR2FpdujUs3WBhgAFcmJjm1hobm5i6cEUY5tCLmRlGmLlp_fVyvbXRhSsOOc95-XgQesnom6Zh6jSkiTS0oYQqrh6hY6aEIJpT9rjWQhnStkYcoWelfKdUKC7pU3TEOWtVrY_R7XnMZSFDnADPMHY5DfHnOrrudB6chy7heVgLXrIry_q7gd3UY7-FMS1byG6-w3HCF5svDZlTiUvcAXb9zk0eenxTp3L02O-3-S3-tPn2-ep6QzRjz9GT4IYCL-7XE_T1fHN9dkEurz58PHt_SbzgaiG9E95704HotWyF4MANleCFCkb2TLZcmDaYnmottXZBeqbaxkuQEIJjHT9B7w6589qN0HuY6lsGO-c4unxnk4v2384Ut_Ym7awWjHEjasDr-4CcfqxQFjvG4mEY3ARpLbYR0nDRasUqSg6oz6mUDOHhGEbt3pattuzelt3bqvyrv-_2QP_RUwFzAMK6rBmKj1A_0h52dSL66u0_4b8AknKmbg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2459346871</pqid></control><display><type>article</type><title>First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811</title><source>Open Access: PubMed Central</source><creator>Chung, Hyun Cheol ; Bang, Yung-Jue ; S Fuchs, Charles ; Qin, Shu-Kui ; Satoh, Taroh ; Shitara, Kohei ; Tabernero, Josep ; Van Cutsem, Eric ; Alsina, Maria ; Cao, Zhu Alexander ; Lu, Jia ; Bhagia, Pooja ; Shih, Chie-Schin ; Janjigian, Yelena Y</creator><creatorcontrib>Chung, Hyun Cheol ; Bang, Yung-Jue ; S Fuchs, Charles ; Qin, Shu-Kui ; Satoh, Taroh ; Shitara, Kohei ; Tabernero, Josep ; Van Cutsem, Eric ; Alsina, Maria ; Cao, Zhu Alexander ; Lu, Jia ; Bhagia, Pooja ; Shih, Chie-Schin ; Janjigian, Yelena Y</creatorcontrib><description>Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Clinical trial registration: NCT03615326 (
)</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2020-0737</identifier><identifier>PMID: 33167735</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>chemotherapy ; Clinical Trial Protocol ; first-line therapy ; gastric cancer ; gastroesophageal junction cancer ; human epidermal growth factor receptor 2 ; pembrolizumab ; trastuzumab</subject><ispartof>Future oncology (London, England), 2021-02, Vol.17 (5), p.491-501</ispartof><rights>2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.</rights><rights>2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-da4ccc9be4d856443e3905ec47f95d1563496f9d088588af5c1762c5e5effa1b3</citedby><cites>FETCH-LOGICAL-c437t-da4ccc9be4d856443e3905ec47f95d1563496f9d088588af5c1762c5e5effa1b3</cites><orcidid>0000-0002-0920-9471</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411394/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411394/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33167735$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chung, Hyun Cheol</creatorcontrib><creatorcontrib>Bang, Yung-Jue</creatorcontrib><creatorcontrib>S Fuchs, Charles</creatorcontrib><creatorcontrib>Qin, Shu-Kui</creatorcontrib><creatorcontrib>Satoh, Taroh</creatorcontrib><creatorcontrib>Shitara, Kohei</creatorcontrib><creatorcontrib>Tabernero, Josep</creatorcontrib><creatorcontrib>Van Cutsem, Eric</creatorcontrib><creatorcontrib>Alsina, Maria</creatorcontrib><creatorcontrib>Cao, Zhu Alexander</creatorcontrib><creatorcontrib>Lu, Jia</creatorcontrib><creatorcontrib>Bhagia, Pooja</creatorcontrib><creatorcontrib>Shih, Chie-Schin</creatorcontrib><creatorcontrib>Janjigian, Yelena Y</creatorcontrib><title>First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Clinical trial registration: NCT03615326 (
)</description><subject>chemotherapy</subject><subject>Clinical Trial Protocol</subject><subject>first-line therapy</subject><subject>gastric cancer</subject><subject>gastroesophageal junction cancer</subject><subject>human epidermal growth factor receptor 2</subject><subject>pembrolizumab</subject><subject>trastuzumab</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kU1vFSEUhonR2FpdujUs3WBhgAFcmJjm1hobm5i6cEUY5tCLmRlGmLlp_fVyvbXRhSsOOc95-XgQesnom6Zh6jSkiTS0oYQqrh6hY6aEIJpT9rjWQhnStkYcoWelfKdUKC7pU3TEOWtVrY_R7XnMZSFDnADPMHY5DfHnOrrudB6chy7heVgLXrIry_q7gd3UY7-FMS1byG6-w3HCF5svDZlTiUvcAXb9zk0eenxTp3L02O-3-S3-tPn2-ep6QzRjz9GT4IYCL-7XE_T1fHN9dkEurz58PHt_SbzgaiG9E95704HotWyF4MANleCFCkb2TLZcmDaYnmottXZBeqbaxkuQEIJjHT9B7w6589qN0HuY6lsGO-c4unxnk4v2384Ut_Ym7awWjHEjasDr-4CcfqxQFjvG4mEY3ARpLbYR0nDRasUqSg6oz6mUDOHhGEbt3pattuzelt3bqvyrv-_2QP_RUwFzAMK6rBmKj1A_0h52dSL66u0_4b8AknKmbg</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Chung, Hyun Cheol</creator><creator>Bang, Yung-Jue</creator><creator>S Fuchs, Charles</creator><creator>Qin, Shu-Kui</creator><creator>Satoh, Taroh</creator><creator>Shitara, Kohei</creator><creator>Tabernero, Josep</creator><creator>Van Cutsem, Eric</creator><creator>Alsina, Maria</creator><creator>Cao, Zhu Alexander</creator><creator>Lu, Jia</creator><creator>Bhagia, Pooja</creator><creator>Shih, Chie-Schin</creator><creator>Janjigian, Yelena Y</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0920-9471</orcidid></search><sort><creationdate>20210201</creationdate><title>First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811</title><author>Chung, Hyun Cheol ; Bang, Yung-Jue ; S Fuchs, Charles ; Qin, Shu-Kui ; Satoh, Taroh ; Shitara, Kohei ; Tabernero, Josep ; Van Cutsem, Eric ; Alsina, Maria ; Cao, Zhu Alexander ; Lu, Jia ; Bhagia, Pooja ; Shih, Chie-Schin ; Janjigian, Yelena Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-da4ccc9be4d856443e3905ec47f95d1563496f9d088588af5c1762c5e5effa1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>chemotherapy</topic><topic>Clinical Trial Protocol</topic><topic>first-line therapy</topic><topic>gastric cancer</topic><topic>gastroesophageal junction cancer</topic><topic>human epidermal growth factor receptor 2</topic><topic>pembrolizumab</topic><topic>trastuzumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chung, Hyun Cheol</creatorcontrib><creatorcontrib>Bang, Yung-Jue</creatorcontrib><creatorcontrib>S Fuchs, Charles</creatorcontrib><creatorcontrib>Qin, Shu-Kui</creatorcontrib><creatorcontrib>Satoh, Taroh</creatorcontrib><creatorcontrib>Shitara, Kohei</creatorcontrib><creatorcontrib>Tabernero, Josep</creatorcontrib><creatorcontrib>Van Cutsem, Eric</creatorcontrib><creatorcontrib>Alsina, Maria</creatorcontrib><creatorcontrib>Cao, Zhu Alexander</creatorcontrib><creatorcontrib>Lu, Jia</creatorcontrib><creatorcontrib>Bhagia, Pooja</creatorcontrib><creatorcontrib>Shih, Chie-Schin</creatorcontrib><creatorcontrib>Janjigian, Yelena Y</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chung, Hyun Cheol</au><au>Bang, Yung-Jue</au><au>S Fuchs, Charles</au><au>Qin, Shu-Kui</au><au>Satoh, Taroh</au><au>Shitara, Kohei</au><au>Tabernero, Josep</au><au>Van Cutsem, Eric</au><au>Alsina, Maria</au><au>Cao, Zhu Alexander</au><au>Lu, Jia</au><au>Bhagia, Pooja</au><au>Shih, Chie-Schin</au><au>Janjigian, Yelena Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>17</volume><issue>5</issue><spage>491</spage><epage>501</epage><pages>491-501</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Clinical trial registration: NCT03615326 (
)</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>33167735</pmid><doi>10.2217/fon-2020-0737</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0920-9471</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2021-02, Vol.17 (5), p.491-501 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8411394 |
| source | Open Access: PubMed Central |
| subjects | chemotherapy Clinical Trial Protocol first-line therapy gastric cancer gastroesophageal junction cancer human epidermal growth factor receptor 2 pembrolizumab trastuzumab |
| title | First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A40%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First-line%20pembrolizumab/placebo%20plus%20trastuzumab%20and%20chemotherapy%20in%20HER2-positive%20advanced%20gastric%20cancer:%20KEYNOTE-811&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Chung,%20Hyun%20Cheol&rft.date=2021-02-01&rft.volume=17&rft.issue=5&rft.spage=491&rft.epage=501&rft.pages=491-501&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2020-0737&rft_dat=%3Cproquest_pubme%3E2459346871%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c437t-da4ccc9be4d856443e3905ec47f95d1563496f9d088588af5c1762c5e5effa1b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2459346871&rft_id=info:pmid/33167735&rfr_iscdi=true |